Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 20,549	$ 4,612
Short-term investments	119,629	46,490
Prepaid expenses and other current assets	3,552	5,027
Total current assets	143,730	56,129
Operating lease right-of-use asset, net	926	365
In-process research and development	32,386	32,386
Other assets	363	186
Total assets	177,405	89,066
Current liabilities:
Accounts payable	5,833	967
Current operating lease liability	314	383
Accrued expenses and other liabilities	5,430	2,545
Total current liabilities	11,577	3,895
Deferred tax liability	2,183	1,752
Non-current operating lease liability	640
Warrant liabilities	44,865	76,211
Total liabilities	59,265	81,858
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2024 and 2023; 59,789,275 and 24,213,130 shares issued and outstanding at December 31, 2024 and 2023, respectively	60	24
Additional paid-in capital	473,640	326,586
Accumulated other comprehensive income	26
Accumulated deficit	(355,586)	(319,402)
Total stockholders’ equity	118,140	7,208
Total liabilities and stockholders’ equity	177,405	89,066
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series X Non-Voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).